<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230105057060N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-06</date_registration>
      <primary_sponsor>Yasouj University of Medical Sciences</primary_sponsor>
      <public_title>The effect of hydroalcoholic extract of Quercus brantii on acute watery diarrhea in children</public_title>
      <acronym></acronym>
      <scientific_title>The effect of hydroalcoholic extract of Quercus brantii on acute watery diarrhea: A double-blind clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67891</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The technique of randomization is simple. The computer program "Computer Random Generation" will determine the assignment sequence. We will use sealed envelopes with codes to assign research units to the control and intervention groups (A, B), Blinding description: The study will be conducted in a double-blind manner, so that the pharmacist will provide researchers with 80 bottles containing medicine (500 mg of oak extract) and placebo, which will have a code on each of 
them. The researcher and patients are not aware of its contents.</study_design>
      <phase>0 (exploratory trials)</phase>
      <hc_freetext>Diarrhea in children.</hc_freetext>
      <i_freetext>Intervention 1: The study is a randomized, a double-blind clinical trial including 80 children (6 to 6 years old) with severe watery diarrhea (no blood in stool and fewer than five white blood cells) for 3 to 6 days that were hospitalized in the hospital of Imam Sajjad Yasuj. The subjects are typically assigned to the control or intervention group using a simple random assignment method after completing an ethical form. The parents will being thoroughly informed about participating in the research. The study will begin after receiving the code of ethics from the university. Patients with watery diarrhea are admitted to Imam Sajjad Hospital in Yasuj city after taking a history and examining related tests, including blood and urine tests, including CBC-Diff, Na, K, BUN, Cr, BS, S/E. U/A are selected and randomly divided into two control and intervention groups, The study will be done in a double-blind manner. After preparing 80 bottles of simple syrup containing extract and placebo, the researcher and patient need to be made aware of the contents of the bottles because they are coded. The patient or the patient's companion is first given a questionnaire containing study variables such as fever, patient weight, and duration of hospitalization. The intervention group received 500 mg of oak extract orally in addition to the standard treatment for acute watery diarrhea (WHO protocol). In contrast, the control group received a placebo and the standard treatment for acute watery diarrhea (WHO protocol). The questionnaires are then filled out a second time with daily references for up to three days. After the collated questionnaires are made available to the statistician after the survey. In addition, supportive remedies, such as zinc and probiotics, are administered to aid in the regeneration of the villi. Intervention 2: Control group: placebo group:The same amount of placebo substance was used in containers that were completely similar to containers containing oak extract.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only a part of the data, such as the information related to the main outcome or the like, can be shared.

When:
2023

To whom:
Academic and scientific institutions

Conditions:
Data validation

Where to obtain:
Dr Zeynab Daneshi

How to obtain:
Contact the project manager

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Keshtkari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Jalil Street</address>
        <city>Yasouj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7591994779</zip>
        <telephone>+98 74 3323 5137</telephone>
        <email>a_keshtkari@yahoo.com</email>
        <affiliation>Yasouj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Keshtkari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Jalil Street</address>
        <city>Yasouj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7591994779</zip>
        <telephone>+98 74 3323 5137</telephone>
        <email>a_keshtkari@yahoo.com</email>
        <affiliation>Yasouj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 6-72 month
Acute watery diarrhea in children
Informed consent of the patient's parents</inclusion_criteria>
      <agemin>6 months</agemin>
      <agemax>6 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Chronic Diseases
Severe malnutrition
Bloody diarrhea
Recent use of antibiotics
Persistent vomiting
Recent use of zinc supplements (last month)
Drug intolerance</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R19.7</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diarrhea, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The study is a randomized, a double-blind clinical trial including 80 children (6 to 6 years old) with severe watery diarrhea (no blood in stool and fewer than five white blood cells) for 3 to 6 days that were hospitalized in the hospital of Imam Sajjad Yasuj. The subjects are typically assigned to the control or intervention group using a simple random assignment method after completing an ethical form. The parents will being thoroughly informed about participating in the research. The study will begin after receiving the code of ethics from the university. Patients with watery diarrhea are admitted to Imam Sajjad Hospital in Yasuj city after taking a history and examining related tests, including blood and urine tests, including CBC-Diff, Na, K, BUN, Cr, BS, S/E. U/A are selected and randomly divided into two control and intervention groups, The study will be done in a double-blind manner. After preparing 80 bottles of simple syrup containing extract and placebo, the researcher and patient need to be made aware of the contents of the bottles because they are coded. The patient or the patient's companion is first given a questionnaire containing study variables such as fever, patient weight, and duration of hospitalization. The intervention group received 500 mg of oak extract orally in addition to the standard treatment for acute watery diarrhea (WHO protocol). In contrast, the control group received a placebo and the standard treatment for acute watery diarrhea (WHO protocol). The questionnaires are then filled out a second time with daily references for up to three days. After the collated questionnaires are made available to the statistician after the survey. In addition, supportive remedies, such as zinc and probiotics, are administered to aid in the regeneration of the villi.</i_keyword>
      <i_keyword>Control group: placebo group:The same amount of placebo substance was used in containers that were completely similar to containers containing oak extract.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Children's weight. Timepoint: Hospitalization period. Method of measurement: Balance.</prim_outcome>
      <prim_outcome>Frequency of diarrhea. Timepoint: The first and the last day of hospitalization. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>Stool consistency. Timepoint: Examining stool consistency (watery, soft and hard) on the first, second and third day based on the daily stool consistency record form (Bristol scoring form). Method of measurement: Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Blood and urine tests including CBC-Diff, Na, K, BUN, Cr, BS, S/E, U/A. Timepoint: Before and after the study period. Method of measurement: Laboratory.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yasouj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-18</approval_date>
        <contact_name>Research Ethics Committees</contact_name>
        <contact_address>Jalil Yasuj Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
